Search Results for: Johnson & Johnson
Trending Dietlongevity
The Buffett Paradox: Cola, Happiness, and a Biotech Longevity Enigma
2025-05-11
Trending R&D investment
Bristol Myers Squibb Bets Big on America with $40 Billion Investment Plan
2025-05-07
Trending Trump Administration
Can the FDA Speed Up Drug Factory Construction? Trump’s Order Aims to Make It Happen
2025-05-07
Interviews medtechIndustry
Climbing the MedTech Mountain: How Startups can Tackle Clinical, Payer, and Exit Peaks
2025-05-06
News Flash
Amgen’s Biosimilar Revenue Boosted by $150 Million in Sales of J&J Copycat Drug in Q1
2025-05-02
Trending Roche
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
News Flash
Johnson & Johnson Forecasts $400 Million Tariff Impact in 2025, But Raises Sales Outlook
2025-04-16
News Flash
Johnson & Johnson Raises 2025 Sales Forecast Despite Anticipating $400 Million in Tariff Costs
2025-04-15
Trending Trump AdministrationU.S. tariffs
Trump’s Plan to Impose Major Drug Tariffs Sparks Fears Over Global Access and Pharma Supply Chains
2025-04-10
Industry layoffs
Pharma Layoffs: Strategic Downsizing or Long-Term Risk?
2025-03-31
Manufacturing MerckFacility
Merck Launches $1 Billion Vaccine Facility in North Carolina, Boosting U.S. Manufacturing and Job Creation
2025-03-13
M&A BMS
Bristol Myers Squibb Acquires Cancer Cell Therapy Partner 2seventy Bio in $286M Deal
2025-03-12
Trending MerckPatent
Merck Faces Patent Battle with Halozyme Over Latest Keytruda Injection
2025-03-09
Industry Pharma patent cliff
Pharma Faces $236 Billion Patent Cliff by 2030: Key Drugs and Companies at Risk
2025-03-07
Deals Cardiovascular
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
1 2 3 … 12
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2025 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top